Upcoming live webinar

Exploring tumor-informed ctDNA-guided interventions in melanoma

Date: Thursday, May 14, 2026

Time: 4:00 PM CT | 2:00 PM PT | 5:00 PM ET

Webinar duration: 60 minutes

Registrants will receive a recording of the webinar approximately one week after the event.

Transformative real-world insights and clinical applications from longitudinal tumor-informed ctDNA monitoring.

Join us for an insightful webinar exploring findings from a recent multi-center, real-world study, “Longitudinal ctDNA Monitoring for Post-Surgical Disease Surveillance in Patients with Stage I–IIIB Melanoma.”

Key topics include:

Tumor-informed ctDNA as a biomarker: Learn how ctDNA detection can provide early insight into melanoma recurrence and progression
Real-world evidence: Explore study findings on tumor-informed ctDNA-guided interventions and their potential to improve patient outcomes
Clinical applications: Understand how Signatera™ results may guide care decisions, including imaging escalation, therapy initiation, and management of molecular recurrence

Webinar highlights:

Speaker: Hear from the lead author George Ansstas, MD, on his publication, “Longitudinal ctDNA Monitoring for Post-Surgical Disease Surveillance in Patients with Stage I–IIIB Melanoma.”
Interactive Q&A: Engage with the researchers and ask questions about the study’s methodology, results, and implications
Case studies: Review real-world examples of ctDNA-driven changes in clinical care

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers

George Ansstas, MD

Professor of Medicine, Section of Medical Oncology

Division of Oncology, WashU Medicine

Dr. George Ansstas is a melanoma specialist and academic leader at Washington University School of Medicine in St. Louis, where he serves as Director of Melanoma and Professor of Medicine. His research program focuses on identifying actionable genomic alterations in melanoma and other skin cancers to enable rational drug repurposing. A central theme of his work is defining homologous recombination deficiency (“HRDness”) in cutaneous and mucosal malignancies and expanding the therapeutic role of PARP inhibitors beyond their traditional indications. Dr. Ansstas has also reported novel clinical observations of exceptional, deep, and durable responses in heavily pretreated, refractory melanoma patients treated with combined MEK inhibition and Talimogene laherparepvec (T-VEC), supporting the development of biologically driven combination strategies in melanoma. In addition, Dr. Ansstas has clinical and research interests in the use of early biomarkers such as circulating tumor DNA (ctDNA) to monitor response and tailor treatment in real time for patients.

Michael Krainock, MD, PhD

Medical Director, Oncology

Natera

A trained cardiothoracic surgeon and translational scientist, he completed his MD at the University of Nevada, PhD at the University of Southern California, and surgical training at Loma Linda University Medical Center and the University of Pittsburgh Medical Center.

Dr. Krainock combines his clinical and research expertise to advance the use of ctDNA technologies, particularly Natera’s Signatera™ test for MRD detection and precision oncology applications

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy